An Army-sponsored phase III clinical trial (RV144) involving more than 16,000 adult volunteers in Thailand showed that an investigational HIV vaccine regimen was safe and modestly effective in preventing HIV infection.
4/23/2012
A Phase I clinical trial beginning this month in Kericho, Kenya and later in Tanzania and Uganda, will evaluate a new vaccine combination.
4/11/2012
This small clinical trial will evaluate extended boosting regimens using the same vaccine components that were used in RV144.
4/4/2012
Researchers have discovered important clues about the immune responses that may have played a role in protecting some volunteers from HIV in the RV144 Thai trial.
MHRP Profiles
Meet Dr. Milton Omondi, Program Director of the Walter Reed Project (WRP) HIV/AIDS Program, Kisumu West (Kenya). “I feel inspired by the positive impact that the program has had in Kisumu West District,” noted Omondi when asked what he enjoys most about his job.
Jerome Kim, M.D.
Principal Deputy, MHRP and COL, MC, U.S. Army
After two years of extensive laboratory studies following the landmark RV144 trial, investigators from the Army, led by COL Kim, and Duke University have found new clues about the immune responses that may play a role in protection from HIV. In this video, COL Kim discusses the results, which are published in the New England Journal of Medicine.
MHRP oversees all HIV testing for the Army and serves as the Tri-Service Reference Laboratory.
 |
 |
 |
 |
Have a Question For Us? Contact Us.
MHRP is part of the Walter Reed Army Institute of Research
©2012 U.S. Military HIV Research Program
